Please ensure Javascript is enabled for purposes of website accessibility

Why Jazz Pharmaceuticals Sang Off-Key in Q1

By Keith Speights - May 6, 2020 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker missed Wall Street top- and bottom-line estimates in the first quarter.

Jazz Pharmaceuticals (JAZZ 0.25%) ended 2019 on a positive note, with shares up 20%. This year has been disastrous, though. Jazz stock is down more than 30%, wiping out all of the 2019 gains and then some. 

The drugmaker announced its first-quarter results after the market closed on Tuesday. Shares sank 6% in after-hours trading, providing a clue as to what investors thought about the company's update. Here's why Jazz sang off-key in Q1.

Person in lab coat, safety goggles, and face mask holding a pill in their gloved hand.

Image source: Getty Images.

By the numbers

Jazz reported first-quarter revenue of $534.7 million, up 5% year over year. However, that increase wasn't nearly enough to impress Wall Street analysts. The consensus analysts' estimate called for Q1 revenue of $544.6 million.

The drugmaker posted a net loss in the first quarter of $157.8 million, or $2.82 per share, based on generally accepted accounting principles (GAAP). This result was significantly worse than Jazz's GAAP net income of $85.2 million, or $1.47 per share, recorded in the prior-year period.

Jazz announced adjusted net income in the first quarter of $25.8 million, or $0.45 per share. This also reflected deterioration from the 2019 Q1 adjusted earnings of $164.2 million, or $2.83 per share. And it fell far short of the average analyst's adjusted earnings estimate of $0.67 per share.

Behind the numbers

There were some bright spots in Jazz's Q1 update. Net product sales for narcolepsy drug Xyrem increased 11% year over year to $408 million. Sales for Defitelio/defibrotide jumped 14% year over year. Sales for Vyxeos rose 1.3%, driven mainly by higher demand in Europe. In addition, prescription volume for sleep-disorder drug Sunosi in Q1 soared 41% from the fourth quarter of 2019.

However, sales of blood cancer drug Erwinaze/Erwinase plunged 38% from the prior-year period. Jazz attributed the decline to ongoing supply and manufacturing issues. Also, sales for Sunosi were negatively impacted by the COVID-19 pandemic and by increased coupon utilization by patients.

Jazz's poor bottom-line performance wasn't as bad as it looked at first glance. The company recorded a $200 million up-front payment in Q1 to Pharma Mar for U.S. rights to cancer drug lurbinectedin. Jazz also took a $136.1 million hit from an impairment charge related to its decision to stop enrollment of the late-stage clinical study of defibrotide in preventing veno-occlusive disease (VOD).

Looking ahead

Due to the impact of the COVID-19 pandemic, Jazz lowered its full-year 2020 guidance. The company now expects revenue of between $2.12 billion and $2.26 billion, down from its previous outlook of $2.32 billion to $2.4 billion.

There are several potential catalysts on the way for the biotech stock. Jazz hopes to win FDA approval by July 21, 2020, for JZP-458 in treating cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. It also anticipates an FDA approval decision for lurbinectedin in treating relapsed small cell lung cancer by Aug. 16, 2020.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
JAZZ
$160.44 (0.25%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.